Avelumab vs Docetaxel for Previously Treated Advanced NSCLC: Primary Analysis of the Phase 3 JAVELIN Lung 200 Trial

Barlesi, F.Vansteenkiste, J.Spigel, D.Ishii, H.Garassino, M.De Marinis, F.Ozguroglu, M.Szczesna, A.Polychronis, A.Uslu, R.Krzakowski, M.Lee, J.Calabro, L.Frontera, O.Ellers-Lenz, B.Bajars, M.Ruisi, M.Parki, K.2019-10-272019-10-2720181556-08641556-1380https://doi.org/10.1016/j.jtho.2018.08.260https://hdl.handle.net/11454/29847en10.1016/j.jtho.2018.08.260info:eu-repo/semantics/closedAccessPhase 3avelumabdocetaxelAvelumab vs Docetaxel for Previously Treated Advanced NSCLC: Primary Analysis of the Phase 3 JAVELIN Lung 200 TrialConference Object1310S331S332WOS:000454014500244Q1